相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study
David Martinez-Cuadron et al.
BLOOD ADVANCES (2022)
Transplant outcomes after CPX-351 vs 7+3 in older adults with newly diagnosed high-risk and/or secondary AML
Geoffrey L. Uy et al.
BLOOD ADVANCES (2022)
Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia
Andrew H. Matthews et al.
BLOOD ADVANCES (2022)
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
Daniel A. Arber et al.
BLOOD (2022)
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms
Joseph D. Khoury et al.
LEUKEMIA (2022)
Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine
Daniel A. Pollyea et al.
CLINICAL CANCER RESEARCH (2022)
Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes
David A. Sallman et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial
Michael Heuser et al.
ANNALS OF HEMATOLOGY (2021)
Diagnostic and therapeutic pitfalls in NPM1-mutated AML: notes from the field
Brunangelo Falini et al.
LEUKEMIA (2021)
Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia
Evan M. Cherry et al.
BLOOD ADVANCES (2021)
CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial
Jeffrey E Lancet et al.
Lancet Haematology (2021)
Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease
Christopher S. Hourigan et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Comparison of therapy-related and de novo core binding factor acute myeloid leukemia: A bone marrow pathology group study
Heesun J. Rogers et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial
Andrew H. Wei et al.
BLOOD (2020)
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
C. D. DiNardo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Cancer therapy shapes the fitness landscape of clonal hematopoiesis
Kelly L. Bolton et al.
NATURE GENETICS (2020)
TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML
Jayakumar Vadakekolathu et al.
BLOOD ADVANCES (2020)
Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS): Updated Results from a Phase 1b Study
Andrew M. Brunner et al.
BLOOD (2020)
Secondary Acute Myeloid Leukemia and the Role of Allogeneic Stem Cell Transplantation in a Population-Based Setting
Christer Nilsson et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Efficacy outcomes in the treatment of older or medically unfit patients with acute myeloid leukaemia: A systematic review and meta-analysis
A. Stone et al.
LEUKEMIA RESEARCH (2019)
Genetic Characteristics and Outcomes By Mutation Status in a Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed, High-Risk/Secondary Acute Myeloid Leukemia (AML)
R. Coleman Lindsley et al.
BLOOD (2019)
Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome
Jorge E. Cortes et al.
LEUKEMIA (2019)
Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation
Maria H. Gilleece et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
Jeffrey E. Lancet et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia
Prajwal Boddu et al.
LEUKEMIA & LYMPHOMA (2018)
Conditioning intensity in secondary AML with prior myelodysplastic syndrome/myeloproliferative disorders: an EBMT ALWP study
Salyka Sengsayadeth et al.
BLOOD ADVANCES (2018)
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Doehner et al.
BLOOD (2017)
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
R. M. Stone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Therapy-related myeloid neoplasms: when genetics and environment collide
Megan E. McNerney et al.
NATURE REVIEWS CANCER (2017)
Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly
Florian Zink et al.
BLOOD (2017)
Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial
Christophe Willekens et al.
HAEMATOLOGICA (2016)
Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial
Christophe Willekens et al.
HAEMATOLOGICA (2016)
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber et al.
BLOOD (2016)
Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study
Lene Sofie Granfeldt Ostgard et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Acute myeloid leukemia ontogeny is defined by distinct somatic mutations
R. Coleman Lindsley et al.
BLOOD (2015)
Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials
Robert K. Hills et al.
LANCET ONCOLOGY (2014)
Clinical and Pathologic Features of Secondary Acute Promyelocytic Leukemia
Amy S. Duffield et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2012)
Prognostic Significance of the European LeukemiaNet Standardized System for Reporting Cytogenetic and Molecular Alterations in Adults With Acute Myeloid Leukemia
Krzysztof Mrozek et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML
Sabine Kayser et al.
BLOOD (2011)
CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells
Ravindra Majeti et al.
CELL (2009)
Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission Systematic Review and Meta-analysis of Prospective Clinical Trials
John Koreth et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia
Bob Lowenberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia
Richard F. Schlenk et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
分享论文
